23 Sep 2025
Early discovery development of antibody-drug conjugates (ADCs) requires answering key questions that define therapeutic success. Selecting a target antigen with high tumor specificity, an antibody with strong binding and stability, and a payload-linker system that ensures potency is critical. Furthermore, evaluating in vivo efficacy, pharmacokinetics and biodistribution is also essential. These complex considerations demand specialized experience and substantial resources. With Labcorp, you have access to industryleading capabilities to streamline development and accelerate the timeline to clinical application.